What is Accendra Health's operating income?

Accendra Health's total operating income in 2025 was $27.46 million, based on the following breakdown: Total Gross Profit: $1.29 billion Total Operating Expenses: $1.26 billion

Accendra Health (ACH) Financials

$1.23 +0.02 (+1.24%)

As of 08/28/2026 03:58 PM Eastern

Compare

Annual Income Statements for Accendra Health

This table shows Accendra Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	103	109	73	-437	-62	30	222	22	-41	-363	-1,101
Consolidated Net Income / (Loss)	103	109	73	-437	-62	30	222	22	-41	-363	-1,101
Net Income / (Loss) Continuing Operations	103	109	73	-395	-23	88	0.00	22	8.91	-351	-103
Total Pre-Tax Income	173	173	57	-427	-29	110	277	11	15	-330	-102
Total Operating Income	200	200	89	-352	73	204	368	143	133	-218	27
Total Gross Profit	1,215	1,187	1,172	1,071	1,128	1,281	1,513	1,826	1,217	1,280	1,289
Total Revenue	9,773	9,723	9,318	9,418	9,211	8,480	9,785	9,955	2,553	2,680	2,762
Operating Revenue	9,773	9,723	9,318	9,418	9,211	8,480	9,785	9,955	2,553	2,680	2,762
Total Cost of Revenue	8,558	8,536	8,146	8,348	8,082	7,199	8,272	8,129	1,336	1,400	1,473
Operating Cost of Revenue	8,558	8,536	8,146	8,348	8,082	7,199	8,272	8,129	1,336	1,400	1,473
Total Operating Expenses	1,014	988	1,083	1,423	1,055	1,077	1,145	1,683	1,084	1,498	1,262
Selling, General & Admin Expense	994	970	1,017	953	1,023	1,041	1,077	1,555	1,002	1,082	1,068
Amortization Expense	-	-	-	-	-	-	43	127	75	62	96
Other Operating Expenses / (Income)	-7.97	-7.39	4.93	-3.04	2.23	-2.37	-6.19	-5.25	0.00	0.00	80
Impairment Charge	-	0.00	0.00	414	-	-	-	0.00	0.00	307	0.00
Restructuring Charge	28	25	61	59	30	38	31	6.90	7.34	47	18
Total Other Income / (Expense), net	-27	-27	-32	-75	-102	-94	-92	-132	-118	-112	-129
Interest Expense	27	27	32	71	99	95	89	129	117	108	107
Other Income / (Expense), net	-	-	-	-3.77	-2.93	0.41	-3.20	-3.13	-1.20	-4.59	-22
Income Tax Expense	70	64	-15	-32	-6.14	22	55	-11	6.36	21	0.73
Net Income / (Loss) Discontinued Operations	-	-	-	-42	-40	-58	-	-	-50	-12	-998
Basic Earnings per Share	$1.65	$1.76	$1.20	($7.28)	($1.03)	$0.47	$3.05	$0.30	($0.54)	($4.73)	($14.31)
Weighted Average Basic Shares Outstanding	62.12M	61.09M	61.52M	62.24M	60.60M	73.50M	75.57M	76.28M	76.60M	77.25M	76.44M
Diluted Earnings per Share	$1.65	$1.76	$1.20	($7.28)	($1.03)	$0.47	$2.94	$0.29	($0.53)	($4.73)	($14.31)
Weighted Average Diluted Shares Outstanding	62.12M	61.09M	61.52M	62.24M	60.60M	73.50M	75.57M	76.28M	76.60M	77.25M	76.44M
Weighted Average Basic & Diluted Shares Outstanding	62.12M	61.09M	61.52M	62.24M	60.60M	73.50M	75.57M	76.28M	76.60M	77.25M	76.44M

This table shows Accendra Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	18	-22	-32	-13	-296	-25	-869	-150	-56	-6.47	-89
Consolidated Net Income / (Loss)	18	-22	-32	-13	-296	-25	-869	-150	-56	-6.47	-89
Net Income / (Loss) Continuing Operations	-6.63	-22	-6.74	1.26	-318	-3.81	-84	-5.61	12	-6.47	-89
Total Pre-Tax Income	21	-27	-9.48	0.96	-300	-5.40	-85	-3.64	22	-16	-88
Total Operating Income	60	9.70	17	31	-262	20	-40	26	41	17	-35
Total Gross Profit	570	536	316	332	580	319	325	322	116	278	263
Total Revenue	2,656	2,613	660	687	2,696	674	682	697	-1,249	628	613
Operating Revenue	2,656	2,613	660	687	2,696	674	682	697	-1,249	628	613
Total Cost of Revenue	2,086	2,077	344	355	2,116	355	357	375	-1,366	350	350
Operating Cost of Revenue	2,086	2,077	344	355	2,116	355	357	375	-1,366	350	350
Total Operating Expenses	510	526	299	301	842	299	364	296	76	261	299
Selling, General & Admin Expense	457	478	270	272	493	262	268	266	72	255	244
Amortization Expense	26	20	14	15	25	23	14	29	23	29	29
Other Operating Expenses / (Income)	1.94	0.55	0.00	0.00	-8.23	-	80	0.00	-2.64	-	0.00
Restructuring Charge	24	27	15	14	25	14	2.54	0.66	-16	-24	26
Total Other Income / (Expense), net	-39	-37	-26	-30	-38	-25	-45	-30	-19	-33	-52
Interest Expense	33	36	26	29	37	24	0.00	29	18	32	17
Interest & Investment Income	-	-	-	-	-	-	-26	-	-	-	-35
Other Income / (Expense), net	-5.68	-1.15	-0.82	-1.17	-0.89	-0.98	-19	-1.08	-0.69	-1.02	-0.64
Income Tax Expense	3.21	-5.23	-2.74	-0.30	-3.54	-1.59	-1.13	1.97	9.98	-9.78	1.44
Net Income / (Loss) Discontinued Operations	-	-	-25	-14	-	-21	-785	-145	-	0.00	0.00
Basic Earnings per Share	$0.23	($0.29)	($0.42)	($0.17)	($3.85)	($0.32)	($11.30)	($1.94)	($0.75)	($0.08)	($1.16)
Weighted Average Basic Shares Outstanding	76.60M	76.50M	77.10M	77.11M	77.25M	76.61M	77.24M	77.35M	76.44M	76.58M	76.90M
Diluted Earnings per Share	$0.23	($0.29)	($0.42)	($0.16)	($3.85)	($0.32)	($11.30)	($1.94)	($0.75)	($0.08)	($1.16)
Weighted Average Diluted Shares Outstanding	76.60M	76.50M	77.10M	77.11M	77.25M	76.61M	77.24M	77.35M	76.44M	76.58M	76.90M
Weighted Average Basic & Diluted Shares Outstanding	76.60M	76.50M	77.10M	77.11M	77.25M	76.61M	77.24M	77.35M	76.44M	76.58M	76.90M

This table details how cash moves in and out of Accendra Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	104	24	-81	-1.16	-19	50	-62	14	187	-224	233
Net Cash From Operating Activities	270	188	57	116	166	339	124	325	741	161	-102
Net Cash From Continuing Operating Activities	270	188	57	116	166	339	124	325	741	161	-102
Net Income / (Loss) Continuing Operations	103	109	73	-437	-62	30	222	22	8.91	-351	-103
Consolidated Net Income / (Loss)	103	109	73	-437	-62	30	222	22	-41	-363	-1,101
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	-	-50	-12	-998
Depreciation Expense	66	55	59	102	117	93	91	229	210	181	215
Non-Cash Adjustments To Reconcile Net Income	14	16	21	471	69	124	102	7.23	-14	299	-5.40
Changes in Operating Assets and Liabilities, net	87	7.43	-96	-21	43	92	-290	67	131	15	48
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	-	-	404	18	-256
Net Cash From Investing Activities	-36	-25	-417	-816	-52	80	-54	-1,804	-137	-117	144
Net Cash From Continuing Investing Activities	-36	-25	-417	-816	-52	80	-54	-1,804	-108	-98	199
Purchase of Property, Plant & Equipment	-37	-30	-51	-66	-52	-59	-50	-167	-179	-183	-201
Acquisitions	0.00	0.00	-367	-752	-	0.00	0.00	-1,685	0.00	0.00	-18
Sale of Property, Plant & Equipment	0.14	5.38	0.66	1.69	-	0.00	0.00	48	72	70	78
Divestitures	-	-	-	-	0.00	133	-	-	0.00	0.00	342
Other Investing Activities, net	-	-	-	-	0.33	6.27	-3.94	-1.67	-0.94	15	-1.91
Net Cash From Discontinued Investing Activities	-	-	-	-	-	-	-	-	-29	-18	-55
Net Cash From Financing Activities	-125	-143	273	701	-130	-379	-129	1,497	-417	-268	188
Net Cash From Continuing Financing Activities	-125	-143	273	701	-130	-379	-129	1,497	-411	-250	190
Repayment of Debt	-41	-8.29	-14	-52	-125	-724	-585	-1,246	-887	-2,352	-2,714
Repurchase of Common Equity	-20	-71	-5.00	-	-	-	-	-	0.00	0.00	-10
Issuance of Debt	0.00	0.00	355	801	0.00	155	472	2,743	476	2,102	2,915
Net Cash From Discontinued Financing Activities	-	-	-	-	-	-	-	-	-6.27	-18	-2.13
Other Net Changes in Cash	-	-	-	-1.99	-2.67	9.91	-3.54	-	-	-	1.90
Cash Interest Paid	-	-	-	69	95	90	39	107	153	142	135
Cash Income Taxes Paid	-	-	-	19	-6.20	-17	99	34	-6.28	5.55	12

This table details how cash moves in and out of Accendra Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	23	-2.13	2.68	-198	-26	10	18	-31	236	55	-329
Net Cash From Operating Activities	112	-53	116	27	71	-35	38	-173	68	-50	-26
Net Cash From Continuing Operating Activities	112	-53	116	27	71	-35	38	-173	68	-50	-26
Net Income / (Loss) Continuing Operations	18	-22	-32	-13	-296	-3.81	-869	-150	942	-6.47	-89
Consolidated Net Income / (Loss)	18	-22	-32	-13	-296	-25	-869	-150	-56	-6.47	-89
Depreciation Expense	71	74	64	62	65	43	59	64	30	62	66
Non-Cash Adjustments To Reconcile Net Income	1.69	-5.59	1.11	-0.31	305	-0.53	765	106	-893	-49	4.22
Changes in Operating Assets and Liabilities, net	22	-100	83	-21	-3.39	-7.08	83	-192	246	-56	-6.85
Net Cash From Investing Activities	-39	-1.87	-35	-27	-52	-48	-53	-39	285	54	-31
Net Cash From Continuing Investing Activities	-39	-1.87	-35	-27	-52	-32	-53	-39	340	54	-31
Purchase of Property, Plant & Equipment	-56	-3.41	-46	-62	-71	-48	-125	-58	-9.29	-42	-49
Sale of Property, Plant & Equipment	18	50	17	18	19	17	18	18	25	96	15
Other Investing Activities, net	-0.52	-2.00	-6.86	17	0.47	-0.41	-1.50	-	-	0.00	2.10
Net Cash From Financing Activities	-51	53	-78	-200	-43	93	32	181	-117	51	-272
Net Cash From Continuing Financing Activities	-51	53	-78	-200	-43	96	32	181	-115	51	-272
Repayment of Debt	-51	-152	-541	-819	-858	-680	-816	-631	-584	-218	-1,789
Issuance of Debt	-	205	462	619	815	777	853	812	472	269	1,517
Cash Interest Paid	52	18	53	33	37	27	38	30	39	29	50
Cash Income Taxes Paid	0.52	2.37	2.88	2.37	-2.06	0.13	5.33	3.33	3.69	20	-0.44

This table presents Accendra Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	2,774	2,718	3,376	3,774	3,643	3,336	3,537	5,386	5,093	4,656	2,452
Total Current Assets	1,975	1,962	2,182	2,539	2,407	2,136	2,322	2,295	2,103	2,021	548
Cash & Equivalents	161	185	105	66	67	83	56	69	243	28	282
Accounts Receivable	588	606	759	757	675	701	682	763	598	218	96
Inventories, net	941	916	990	1,274	1,146	1,234	1,496	1,334	1,111	68	74
Other Current Assets	285	254	328	122	79	118	89	129	151	82	96
Plant, Property, & Equipment, net	209	192	206	324	0.00	0.00	0.00	578	544	249	256
Total Noncurrent Assets	590	564	988	911	1,236	1,200	1,215	2,513	2,447	2,386	1,648
Goodwill	420	415	714	414	393	394	390	1,637	1,639	1,228	1,228
Intangible Assets	95	83	184	314	285	243	210	445	362	210	136
Other Noncurrent Operating Assets	75	67	90	85	558	562	615	431	446	216	283
Total Liabilities & Shareholders' Equity	2,774	2,718	3,376	3,774	3,643	3,336	3,537	5,386	5,093	4,656	2,452
Total Liabilities	1,781	1,758	2,361	3,255	3,181	2,624	2,598	4,441	4,169	4,070	2,913
Total Current Liabilities	1,064	1,035	1,310	1,472	1,416	1,346	1,344	1,566	1,892	1,852	947
Short-Term Debt	-	-	-	-	-	-	-	18	207	43	250
Accounts Payable	711	751	948	1,065	808	1,000	1,002	1,147	1,172	360	364
Current Employee Benefit Liabilities	46	45	30	38	54	109	116	93	116	74	69
Other Current Liabilities	307	239	332	179	231	236	226	308	397	295	264
Total Noncurrent Liabilities	718	723	1,051	1,783	1,765	1,278	1,254	2,874	2,277	2,218	1,966
Long-Term Debt	568	565	901	1,648	1,508	986	948	2,483	1,891	1,798	1,800
Capital Lease Obligations	-	-	-	-	117	120	162	-	-	89	70
Other Noncurrent Operating Liabilities	63	68	76	78	99	121	109	330	345	73	95
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	993	960	1,015	518	462	712	939	946	924	586	-461
Total Preferred & Common Equity	993	960	1,015	518	462	712	939	946	924	586	-461
Total Common Equity	993	960	1,015	518	462	712	939	946	924	586	-461
Common Stock	338	342	350	363	377	584	591	571	587	609	620
Retained Earnings	707	686	691	201	138	167	388	410	369	27	-1,080
Accumulated Other Comprehensive Income / (Loss)	-52	-67	-25	-46	-53	-39	-41	-36	-32	-49	-0.89

This table presents Accendra Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	5,310	5,288	5,124	5,208	5,304	5,081	4,856	4,155	4,036	2,416	2,107
Total Current Assets	2,268	2,262	2,130	2,236	2,327	2,117	2,206	2,299	2,132	589	271
Cash & Equivalents	67	286	215	245	244	45	59	38	33	337	7.65
Accounts Receivable	758	673	683	670	662	662	580	196	203	104	120
Inventories, net	1,288	1,168	1,084	1,145	1,231	1,242	1,409	69	64	65	73
Other Current Assets	155	135	148	177	190	167	158	104	68	83	70
Plant, Property, & Equipment, net	0.00	560	540	501	493	499	520	259	260	228	209
Total Noncurrent Assets	3,042	2,466	2,453	2,470	2,484	2,466	2,130	1,597	1,645	1,600	1,627
Goodwill	1,639	1,637	1,635	1,635	1,635	1,642	1,332	1,228	1,228	1,228	1,228
Intangible Assets	425	403	382	343	326	313	285	195	166	107	78
Other Noncurrent Operating Assets	978	426	437	492	523	511	513	174	251	264	321
Total Liabilities & Shareholders' Equity	5,310	5,288	5,124	5,208	5,304	5,081	4,856	4,155	4,036	2,416	2,107
Total Liabilities	4,386	4,392	4,237	4,313	4,443	4,207	4,285	4,436	4,466	2,881	2,658
Total Current Liabilities	1,631	1,692	1,732	1,933	2,131	1,934	1,960	2,675	2,466	1,203	666
Short-Term Debt	-	-	-	208	211	43	50	383	280	581	0.00
Accounts Payable	1,166	1,194	1,182	1,219	1,382	1,338	1,381	357	340	375	353
Current Employee Benefit Liabilities	87	92	106	79	108	100	87	53	45	33	42
Other Current Liabilities	378	405	444	427	430	454	442	422	455	214	272
Total Noncurrent Liabilities	2,755	2,700	2,505	2,380	2,312	2,273	2,325	1,761	2,000	1,678	1,992
Long-Term Debt	2,362	2,310	2,114	1,946	1,872	1,842	1,898	1,595	1,835	1,522	1,718
Capital Lease Obligations	208	-	-	-	-	-	-	81	81	67	63
Other Noncurrent Operating Liabilities	123	335	346	400	411	405	411	85	83	88	211
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	924	896	887	895	861	875	571	-281	-430	-465	-551
Total Preferred & Common Equity	924	896	887	895	861	875	571	-281	-430	-465	-551
Total Common Equity	924	896	887	895	861	875	571	-281	-430	-465	-551
Common Stock	573	575	581	591	595	600	614	621	623	622	625
Retained Earnings	386	357	351	347	315	302	1.02	-872	-1,022	-1,086	-1,175
Accumulated Other Comprehensive Income / (Loss)	-34	-36	-45	-43	-49	-27	-44	-30	-30	-0.80	-1.05

This table displays calculated financial ratios and metrics derived from Accendra Health's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.53%	-0.51%	-4.17%	1.07%	-2.20%	-7.93%	15.39%	1.74%	3.80%	3.55%	3.06%
EBITDA Growth	19.47%	-4.26%	-41.69%	-270.94%	173.53%	59.37%	53.06%	-19.18%	5.05%	-86.48%	635.49%
EBIT Growth	25.59%	-0.38%	-55.28%	-499.00%	119.72%	191.25%	78.60%	-61.73%	-28.70%	-313.15%	102.35%
NOPAT Growth	42.60%	5.21%	-10.18%	-318.21%	120.76%	219.43%	80.37%	-0.42%	-75.10%	-298.81%	112.61%
Net Income Growth	55.50%	5.20%	-33.09%	-700.35%	85.73%	147.89%	641.82%	-89.90%	-284.47%	-778.15%	-203.47%
EPS Growth	55.66%	6.67%	-31.82%	-706.67%	85.85%	145.63%	525.53%	-90.14%	-286.21%	-775.93%	-202.54%
Operating Cash Flow Growth	7,285.40%	-30.55%	-69.75%	103.60%	43.69%	104.25%	-63.39%	161.73%	127.91%	-78.20%	-163.03%
Free Cash Flow Firm Growth	181.21%	-28.76%	-292.50%	12.95%	108.03%	1,224.68%	-88.76%	-3,016.04%	161.57%	-60.72%	-92.02%
Invested Capital Growth	-9.24%	-4.35%	35.29%	3.66%	1.39%	-8.89%	14.85%	69.48%	-17.72%	-14.73%	-5.13%
Revenue Q/Q Growth	-0.04%	-1.21%	0.23%	-2.76%	0.75%	2.06%	1.09%	0.85%	1.03%	0.37%	-74.31%
EBITDA Q/Q Growth	3.69%	-3.72%	-26.13%	-487.41%	468.49%	33.40%	-7.12%	-14.94%	37.77%	-86.05%	523.95%
EBIT Q/Q Growth	9.38%	-4.29%	-39.30%	-163.30%	141.99%	63.20%	-8.43%	-45.24%	1,216.14%	-302.83%	101.73%
NOPAT Q/Q Growth	19.08%	-3.78%	18.04%	-160.51%	143.74%	38.98%	-5.85%	45.17%	1,262.36%	-281.90%	109.86%
Net Income Q/Q Growth	21.19%	-4.36%	-5.34%	-187.14%	78.13%	149.87%	-3.81%	-81.70%	64.72%	-643.44%	17.89%
EPS Q/Q Growth	21.32%	-3.83%	-4.76%	-183.27%	78.13%	147.47%	-9.26%	-81.41%	64.71%	-627.69%	17.85%
Operating Cash Flow Q/Q Growth	123.10%	-10.07%	16.27%	-33.43%	25.65%	14.92%	-14.28%	12.70%	3.46%	-20.15%	-2.84%
Free Cash Flow Firm Q/Q Growth	253.51%	-17.21%	7.05%	46.04%	-42.35%	-57.95%	290.50%	23.62%	4.02%	74.54%	-92.21%
Invested Capital Q/Q Growth	-2.43%	-0.07%	-0.60%	-18.63%	-11.32%	17.73%	10.29%	-1.75%	-0.24%	-12.70%	4.66%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	12.43%	12.21%	12.58%	11.37%	12.25%	15.10%	15.46%	18.35%	20.56%	20.74%	46.68%
EBITDA Margin	2.73%	2.62%	1.60%	-2.70%	2.03%	3.51%	4.66%	3.70%	3.75%	0.49%	7.96%
Operating Margin	2.05%	2.05%	0.96%	-3.74%	0.79%	2.41%	3.77%	1.44%	1.01%	-1.94%	0.99%
EBIT Margin	2.05%	2.05%	0.96%	-3.78%	0.76%	2.41%	3.73%	1.40%	0.96%	-1.99%	0.19%
Profit (Net Income) Margin	1.06%	1.12%	0.78%	-4.64%	-0.68%	0.35%	2.26%	0.22%	-0.40%	-3.39%	-39.85%
Tax Burden Percent	59.70%	63.05%	126.65%	102.32%	217.18%	27.18%	80.07%	205.57%	75.47%	101.49%	1,079.56%
Interest Burden Percent	86.45%	86.44%	64.40%	119.93%	-40.90%	53.74%	75.77%	7.79%	-54.91%	168.21%	-1,949.39%
Effective Tax Rate	40.30%	36.95%	-26.65%	0.00%	0.00%	19.87%	19.93%	-105.57%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	8.13%	9.19%	7.17%	-13.37%	2.71%	8.99%	15.83%	10.94%	2.38%	-5.65%	1.36%
ROIC Less NNEP Spread (ROIC-NNEP)	4.75%	4.85%	0.33%	-31.03%	-5.40%	-1.86%	8.76%	-4.63%	-2.96%	-17.53%	-81.48%
Return on Net Nonoperating Assets (RNNOA)	2.30%	1.95%	0.19%	-43.61%	-15.43%	-3.90%	11.02%	-8.57%	-6.79%	-43.05%	-1,756.96%
Return on Equity (ROE)	10.43%	11.14%	7.37%	-56.98%	-12.72%	5.09%	26.85%	2.38%	-4.42%	-48.70%	-1,755.61%
Cash Return on Invested Capital (CROIC)	17.82%	13.64%	-22.82%	-16.97%	1.33%	18.29%	2.01%	-40.62%	21.82%	10.25%	6.63%
Operating Return on Assets (OROA)	7.27%	7.27%	2.93%	-9.96%	1.89%	5.86%	10.63%	3.13%	1.90%	-4.36%	0.15%
Return on Assets (ROA)	3.75%	3.96%	2.39%	-12.22%	-1.68%	0.86%	6.45%	0.50%	-0.79%	-7.44%	-30.97%
Return on Common Equity (ROCE)	10.43%	11.14%	7.37%	-56.98%	-12.72%	5.09%	26.85%	2.38%	-4.42%	-48.70%	-1,755.61%
Return on Equity Simple (ROE_SIMPLE)	10.42%	11.33%	7.17%	-84.30%	-13.50%	4.20%	23.61%	2.37%	-4.47%	-64.17%	0.00%
Net Operating Profit after Tax (NOPAT)	120	126	113	-247	51	164	295	294	73	-145	19
NOPAT Margin	1.22%	1.29%	1.21%	-2.62%	0.56%	1.93%	3.02%	2.95%	0.71%	-1.36%	0.70%
Net Nonoperating Expense Percent (NNEP)	3.38%	4.34%	6.85%	17.66%	8.11%	10.85%	7.07%	15.57%	5.34%	11.88%	82.84%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	8.52%	2.42%	-6.01%	1.16%
Cost of Revenue to Revenue	87.57%	87.79%	87.42%	88.63%	87.75%	84.90%	84.54%	81.65%	79.44%	79.26%	53.32%
SG&A Expenses to Revenue	10.17%	9.98%	10.91%	10.12%	11.11%	12.28%	11.01%	15.62%	17.55%	17.85%	38.65%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	10.38%	10.16%	11.62%	15.11%	11.46%	12.70%	11.70%	16.91%	19.55%	22.68%	45.69%
Earnings before Interest and Taxes (EBIT)	200	200	89	-356	70	205	365	140	100	-212	5.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	266	255	149	-254	187	298	456	368	387	52	220
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.01	2.05	1.07	0.76	0.70	2.79	3.50	1.57	1.60	1.78	0.00
Price to Tangible Book Value (P/TBV)	4.17	4.25	9.29	0.00	0.00	26.64	9.69	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.20	0.20	0.12	0.04	0.04	0.23	0.34	0.15	0.14	0.09	0.08
Price to Earnings (P/E)	19.28	18.09	14.95	0.00	0.00	66.55	14.81	66.50	0.00	0.00	0.00
Dividend Yield	3.19%	3.19%	5.80%	13.56%	0.19%	0.04%	0.02%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.19%	5.53%	6.69%	0.00%	0.00%	1.50%	6.75%	1.50%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.72	1.75	1.04	1.05	0.99	1.74	2.18	1.16	1.20	1.19	1.49
Enterprise Value to Revenue (EV/Rev)	0.25	0.24	0.20	0.21	0.20	0.36	0.44	0.39	0.32	0.26	0.74
Enterprise Value to EBITDA (EV/EBITDA)	9.02	9.20	12.67	0.00	10.07	10.11	9.51	10.64	8.60	53.74	9.35
Enterprise Value to EBIT (EV/EBIT)	11.99	11.76	21.12	0.00	26.81	14.72	11.87	28.05	33.40	0.00	392.88
Enterprise Value to NOPAT (EV/NOPAT)	20.08	18.65	16.67	0.00	36.77	18.41	14.70	13.34	45.50	0.00	106.90
Enterprise Value to Operating Cash Flow (EV/OCF)	8.89	12.50	33.20	17.08	11.34	8.88	34.92	12.06	4.49	17.41	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	9.16	12.56	0.00	0.00	74.96	9.05	115.94	0.00	4.96	10.66	21.92
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.57	0.59	0.89	3.18	3.52	1.55	1.18	2.64	2.27	3.28	-4.60
Long-Term Debt to Equity	0.57	0.59	0.89	3.18	3.52	1.55	1.18	2.63	2.05	3.20	-4.06
Financial Leverage	0.48	0.40	0.59	1.41	2.86	2.10	1.26	1.85	2.29	2.46	21.56
Leverage Ratio	2.78	2.81	3.08	4.66	7.56	5.94	4.16	4.74	5.60	6.55	56.69
Compound Leverage Factor	2.40	2.43	1.99	5.59	-3.09	3.19	3.15	0.37	-3.08	11.01	-1,105.07
Debt to Total Capital	36.42%	37.03%	47.01%	76.07%	77.86%	60.83%	54.18%	72.56%	69.42%	76.63%	127.78%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.52%	6.85%	1.88%	15.07%
Long-Term Debt to Total Capital	36.42%	37.03%	47.01%	76.07%	77.86%	60.83%	54.18%	72.04%	62.57%	74.75%	112.72%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	63.58%	62.97%	52.99%	23.93%	22.14%	39.17%	45.82%	27.44%	30.58%	23.37%	-27.78%
Debt to EBITDA	2.13	2.21	6.06	-6.48	8.70	3.71	2.43	6.79	5.42	35.43	9.65
Net Debt to EBITDA	1.53	1.49	5.35	-6.22	8.34	3.43	2.31	6.60	4.79	34.48	8.36
Long-Term Debt to EBITDA	2.13	2.21	6.06	-6.48	8.70	3.71	2.43	6.74	4.88	34.56	8.51
Debt to NOPAT	4.75	4.49	7.97	-6.68	31.74	6.76	3.76	8.51	28.67	-12.74	110.30
Net Debt to NOPAT	3.41	3.01	7.04	-6.41	30.44	6.25	3.57	8.28	25.35	-12.41	95.63
Long-Term Debt to NOPAT	4.75	4.49	7.97	-6.68	31.74	6.76	3.76	8.45	25.84	-12.43	97.29
Altman Z-Score	5.18	5.25	3.72	2.67	3.03	3.55	4.35	2.40	2.46	2.34	0.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.86	1.90	1.67	1.72	1.70	1.59	1.73	1.47	1.11	1.08	0.58
Quick Ratio	0.70	0.77	0.66	0.56	0.52	0.58	0.55	0.53	0.44	0.39	0.40
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	262	187	-360	-313	25	333	37	-1,091	672	264	94
Operating Cash Flow to CapEx	740.94%	758.49%	113.38%	180.62%	318.00%	573.08%	249.90%	274.97%	543.37%	129.47%	-82.52%
Free Cash Flow to Firm to Interest Expense	9.66	6.90	-11.32	-4.41	0.25	3.52	0.42	-8.46	4.35	1.82	0.87
Operating Cash Flow to Interest Expense	9.95	6.94	1.79	1.63	1.68	3.59	1.40	2.52	4.80	1.11	-0.95
Operating Cash Flow Less CapEx to Interest Expense	8.61	6.02	0.21	0.73	1.15	2.96	0.84	1.60	3.91	0.25	-2.10
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	3.55	3.54	3.06	2.63	2.48	2.43	2.85	2.23	1.97	2.20	0.78
Accounts Receivable Turnover	16.10	16.29	13.65	12.43	12.87	12.33	14.16	13.78	15.18	16.61	17.58
Inventory Turnover	9.44	9.19	8.55	7.37	6.68	6.05	6.06	5.75	6.72	7.56	20.74
Fixed Asset Turnover	44.23	48.54	46.80	35.51	0.00	0.00	0.00	0.00	18.42	20.32	10.93
Accounts Payable Turnover	12.97	11.68	9.59	8.29	8.63	7.96	8.26	7.56	7.08	7.00	4.07
Days Sales Outstanding (DSO)	22.67	22.41	26.73	29.37	28.36	29.60	25.78	26.49	24.05	21.97	20.76
Days Inventory Outstanding (DIO)	38.67	39.70	42.71	49.49	54.64	60.33	60.22	63.52	54.34	48.25	17.60
Days Payable Outstanding (DPO)	28.14	31.24	38.05	44.00	42.30	45.84	44.17	48.25	51.56	52.15	89.65
Cash Conversion Cycle (CCC)	33.20	30.87	31.40	34.86	40.70	44.09	41.83	41.76	26.83	18.07	-51.30
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,400	1,339	1,812	1,878	1,904	1,735	1,993	3,377	2,779	2,369	1,377
Invested Capital Turnover	6.64	7.10	5.91	5.11	4.87	4.66	5.25	3.71	3.36	4.16	1.95
Increase / (Decrease) in Invested Capital	-143	-61	473	66	26	-169	258	1,384	-598	-409	-75
Enterprise Value (EV)	2,402	2,347	1,885	1,974	1,883	3,011	4,336	3,920	3,329	2,812	2,055
Market Capitalization	1,994	1,968	1,088	393	324	1,988	3,282	1,489	1,474	1,008	217
Book Value per Share	$15.78	$15.61	$16.58	$8.33	$7.35	$9.69	$12.44	$12.40	$12.08	$7.33	($5.96)
Tangible Book Value per Share	$7.60	$7.52	$1.91	($3.37)	($3.44)	$1.02	$4.49	($14.90)	($14.07)	($13.81)	($23.60)
Total Capital	1,561	1,525	1,916	2,166	2,088	1,818	2,048	3,446	3,022	2,419	1,659
Total Debt	568	565	901	1,648	1,625	1,106	1,110	2,501	2,098	1,854	2,120
Total Long-Term Debt	568	565	901	1,648	1,625	1,106	1,110	2,483	1,891	1,808	1,870
Net Debt	407	379	796	1,582	1,558	1,023	1,054	2,431	1,854	1,804	1,838
Capital Expenditures (CapEx)	36	25	50	64	52	59	50	118	136	125	123
Debt-free, Cash-free Net Working Capital (DFCFNWC)	750	742	768	1,000	924	707	922	677	175	143	-431
Debt-free Net Working Capital (DFNWC)	911	927	872	1,067	991	790	978	747	418	193	-149
Net Working Capital (NWC)	911	927	872	1,067	991	790	978	729	211	147	-399
Net Nonoperating Expense (NNE)	16	17	40	190	114	134	73	271	114	217	1,120
Net Nonoperating Obligations (NNO)	407	379	796	1,360	1,442	1,023	1,054	2,431	1,854	1,804	1,838
Total Depreciation and Amortization (D&A)	66	55	59	102	117	93	91	229	287	265	215
Debt-free, Cash-free Net Working Capital to Revenue	7.68%	7.63%	8.24%	10.62%	10.03%	8.34%	9.42%	6.80%	1.69%	1.34%	-15.61%
Debt-free Net Working Capital to Revenue	9.32%	9.54%	9.36%	11.32%	10.76%	9.32%	9.99%	7.50%	4.04%	1.80%	-5.40%
Net Working Capital to Revenue	9.32%	9.54%	9.36%	11.32%	10.76%	9.32%	9.99%	7.32%	2.04%	1.38%	-14.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.65	$1.76	$1.20	($7.28)	($1.03)	$0.47	$3.05	$0.30	($0.54)	($4.73)	($14.31)
Adjusted Weighted Average Basic Shares Outstanding	62.69M	61.04M	61.52M	62.24M	62.85M	73.50M	75.57M	76.28M	76.60M	77.25M	76.44M
Adjusted Diluted Earnings per Share	$1.65	$1.76	$1.20	($7.28)	($1.03)	$0.47	$2.94	$0.29	($0.54)	($4.73)	($14.31)
Adjusted Weighted Average Diluted Shares Outstanding	62.69M	61.04M	61.52M	62.24M	62.85M	73.50M	75.57M	76.28M	76.60M	77.25M	76.44M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$1.20	($7.28)	($1.03)	$0.47	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	62.69M	61.04M	61.52M	62.24M	62.85M	73.50M	75.57M	76.28M	76.60M	77.25M	76.44M
Normalized Net Operating Profit after Tax (NOPAT)	137	141	105	84	72	194	320	105	143	147	32
Normalized NOPAT Margin	1.40%	1.45%	1.13%	0.90%	0.78%	2.29%	3.27%	1.05%	1.38%	1.37%	1.16%
Pre Tax Income Margin	1.77%	1.77%	0.62%	-4.53%	-0.31%	1.30%	2.83%	0.11%	-0.53%	-3.34%	-3.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.38	7.38	2.81	-5.02	0.71	2.16	4.13	1.08	0.65	-1.47	0.05
NOPAT to Interest Expense	4.41	4.65	3.56	-3.47	0.52	1.73	3.33	2.28	0.47	-1.00	0.18
EBIT Less CapEx to Interest Expense	6.04	6.46	1.23	-5.92	0.18	1.54	3.57	0.17	-0.24	-2.33	-1.10
NOPAT Less CapEx to Interest Expense	3.06	3.74	1.98	-4.38	-0.01	1.10	2.77	1.36	-0.41	-1.86	-0.97
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	61.55%	58.26%	86.75%	-11.03%	-8.38%	2.17%	0.33%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	80.89%	123.55%	93.62%	-11.03%	-8.38%	2.17%	0.33%	0.00%	0.00%	0.00%	-0.92%

This table displays calculated financial ratios and metrics derived from Accendra Health's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	77,247,282.00	76,614,139.00	77,244,161.00	-	76,583,702.00	76,904,704.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	77,247,282.00	76,614,139.00	77,244,161.00	-	76,583,702.00	76,904,704.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-0.32	-11.34	-1.95	-	-0.08	-1.16
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.12%	3.56%	4.20%	4.99%	1.50%	-74.21%	3.26%	1.52%	2.39%	-6.84%	-10.07%
EBITDA Growth	559.38%	4.15%	1.40%	-16.29%	-258.04%	-25.32%	-99.43%	-2.22%	123.63%	26.13%	287.46%
EBIT Growth	200.15%	1.46%	95.50%	-16.13%	-583.71%	120.25%	-465.95%	-15.10%	114.41%	-14.42%	39.27%
NOPAT Growth	235.80%	-1.13%	87.28%	1.52%	-460.72%	104.12%	-334.66%	-54.71%	111.37%	-13.47%	11.48%
Net Income Growth	130.67%	10.37%	-13.00%	-98.72%	-1,765.08%	-14.15%	-2,623.21%	-1,076.79%	80.98%	74.11%	89.75%
EPS Growth	130.26%	9.38%	-13.51%	-112.50%	-1,773.91%	-10.34%	-2,590.48%	-1,112.50%	80.57%	75.00%	89.73%
Operating Cash Flow Growth	28.52%	-133.44%	-62.91%	-82.66%	-36.47%	33.79%	-67.62%	-731.78%	-3.96%	-42.81%	-169.15%
Free Cash Flow Firm Growth	145.66%	1,368.25%	-57.85%	-86.82%	-65.22%	-43.22%	487.76%	1,164.14%	-91.49%	207.37%	-95.47%
Invested Capital Growth	-17.72%	-18.22%	-7.54%	-2.55%	-14.73%	-12.29%	-51.51%	-51.51%	-5.13%	-44.33%	-6.60%
Revenue Q/Q Growth	2.49%	-1.64%	2.23%	1.88%	-0.92%	152.65%	-74.09%	2.25%	-279.16%	150.25%	-2.32%
EBITDA Q/Q Growth	24.09%	-33.93%	0.41%	1.70%	-334.26%	120.91%	-99.24%	19,397.39%	-22.05%	11.58%	-61.58%
EBIT Q/Q Growth	100.20%	-84.28%	123.50%	19.23%	-1,254.59%	106.80%	-5,186.10%	143.08%	57.09%	-59.64%	-322.29%
NOPAT Q/Q Growth	204.62%	-86.65%	109.35%	19.24%	-1,182.33%	107.19%	-32,124.19%	166.66%	18.34%	-45.33%	-305.26%
Net Income Q/Q Growth	376.75%	-223.07%	-45.81%	59.99%	-2,218.85%	91.56%	-3,378.74%	82.71%	62.52%	88.52%	-1,277.09%
EPS Q/Q Growth	387.50%	-226.09%	-44.83%	59.52%	-2,164.71%	91.71%	-3,431.25%	82.83%	61.34%	89.33%	-1,350.00%
Operating Cash Flow Q/Q Growth	-29.01%	-147.39%	319.31%	-76.49%	160.01%	-149.39%	207.25%	-558.71%	139.52%	-173.44%	48.07%
Free Cash Flow Firm Q/Q Growth	-2.89%	-2.74%	-62.90%	-62.39%	156.31%	-68.39%	295.33%	3.95%	-93.19%	1,042.42%	-94.40%
Invested Capital Q/Q Growth	-0.24%	0.90%	-3.71%	0.53%	-12.70%	69.38%	-46.76%	0.53%	4.66%	-0.60%	-10.69%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	21.46%	20.50%	20.37%	20.57%	21.50%	47.37%	47.60%	46.21%	0.00%	44.29%	42.95%
EBITDA Margin	4.71%	3.16%	3.11%	3.10%	-7.33%	9.16%	0.07%	12.83%	0.00%	12.40%	4.88%
Operating Margin	2.26%	0.37%	0.76%	0.89%	-9.72%	2.94%	-5.82%	3.80%	0.00%	2.73%	-5.73%
EBIT Margin	2.05%	0.33%	0.71%	0.84%	-9.75%	2.79%	-8.64%	3.64%	0.00%	2.56%	-5.84%
Profit (Net Income) Margin	0.67%	-0.84%	-1.19%	-0.47%	-10.98%	-3.71%	-127.44%	-21.55%	0.00%	-1.03%	-14.52%
Tax Burden Percent	84.70%	80.72%	189.90%	92.62%	98.82%	462.80%	1,023.04%	4,134.14%	-259.51%	39.81%	101.65%
Interest Burden Percent	38.64%	-317.36%	-88.01%	-60.56%	114.00%	-28.69%	144.13%	-14.31%	54.41%	-100.89%	244.82%
Effective Tax Rate	15.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	45.96%	0.00%	0.00%
Return on Invested Capital (ROIC)	6.43%	0.87%	1.99%	2.41%	-28.28%	0.58%	-21.85%	14.18%	0.00%	2.71%	-8.39%
ROIC Less NNEP Spread (ROIC-NNEP)	4.88%	-0.43%	-0.39%	0.82%	-34.44%	-1.47%	-70.91%	4.76%	0.00%	1.72%	-12.22%
Return on Net Nonoperating Assets (RNNOA)	11.19%	-1.04%	-0.87%	1.75%	-84.60%	-3.80%	-419.47%	38.36%	0.00%	60.19%	49.42%
Return on Equity (ROE)	17.62%	-0.18%	1.13%	4.16%	-112.88%	-3.22%	-441.31%	52.54%	0.00%	62.90%	41.03%
Cash Return on Invested Capital (CROIC)	21.82%	22.39%	10.67%	5.50%	10.25%	7.57%	59.81%	59.71%	6.63%	57.86%	8.44%
Operating Return on Assets (OROA)	4.03%	0.65%	1.42%	1.75%	-21.40%	0.41%	-19.63%	8.59%	0.00%	1.92%	-4.94%
Return on Assets (ROA)	1.32%	-1.66%	-2.38%	-0.98%	-24.11%	-0.55%	-289.47%	-50.83%	0.00%	-0.77%	-12.28%
Return on Common Equity (ROCE)	17.62%	-0.18%	1.13%	4.16%	-112.88%	-3.22%	-441.31%	52.54%	0.00%	62.90%	41.03%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-4.33%	-4.93%	-5.58%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	51	6.79	14	17	-183	14	-28	19	22	12	-25
NOPAT Margin	1.91%	0.26%	0.53%	0.62%	-6.80%	2.06%	-4.08%	2.66%	0.00%	1.91%	-4.01%
Net Nonoperating Expense Percent (NNEP)	1.54%	1.30%	2.39%	1.59%	6.16%	2.05%	49.07%	9.42%	5.79%	0.99%	3.83%
Return On Investment Capital (ROIC_SIMPLE)	1.68%	-	-	-	-7.58%	0.55%	-1.56%	1.05%	1.32%	0.70%	-2.00%
Cost of Revenue to Revenue	78.54%	79.50%	79.63%	79.43%	78.50%	52.63%	52.40%	53.79%	0.00%	55.71%	57.05%
SG&A Expenses to Revenue	17.21%	18.28%	17.57%	17.26%	18.29%	38.93%	39.28%	38.13%	0.00%	40.66%	39.72%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	19.20%	20.13%	19.61%	19.68%	31.22%	44.44%	53.42%	42.41%	0.00%	41.56%	48.69%
Earnings before Interest and Taxes (EBIT)	54	8.54	19	23	-263	19	-59	25	40	16	-36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	125	83	83	84	-198	62	0.46	89	70	78	30
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.60	2.37	1.20	1.38	1.78	1.22	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.14	0.20	0.10	0.11	0.09	0.94	0.06	0.03	0.08	0.06	0.10
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.20	1.44	1.06	1.12	1.19	1.05	2.08	1.93	1.49	1.47	1.66
Enterprise Value to Revenue (EV/Rev)	0.32	0.39	0.27	0.29	0.26	3.49	0.25	0.24	0.74	0.74	0.77
Enterprise Value to EBITDA (EV/EBITDA)	8.60	10.32	7.34	8.13	53.74	0.00	0.00	0.00	9.35	8.51	7.22
Enterprise Value to EBIT (EV/EBIT)	33.40	40.37	26.32	29.11	0.00	0.00	0.00	0.00	392.88	798.11	79.32
Enterprise Value to NOPAT (EV/NOPAT)	45.50	55.13	36.03	38.14	0.00	0.00	0.00	0.00	106.90	115.70	99.06
Enterprise Value to Operating Cash Flow (EV/OCF)	4.49	7.61	8.64	15.08	17.41	14.41	26.95	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	4.96	5.77	9.58	20.18	10.66	12.97	2.27	2.11	21.92	1.81	19.04
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.27	2.41	2.42	2.16	3.28	3.41	-7.33	-5.11	-4.60	-4.67	-3.23
Long-Term Debt to Equity	2.05	2.17	2.17	2.11	3.20	3.32	-5.96	-4.46	-4.06	-3.42	-3.23
Financial Leverage	2.29	2.43	2.20	2.12	2.46	2.59	5.92	8.05	21.56	35.04	-4.04
Leverage Ratio	5.60	5.78	6.03	5.79	6.55	6.87	16.32	20.48	56.69	68.47	-7.53
Compound Leverage Factor	2.17	-18.35	-5.31	-3.51	7.46	-1.97	23.52	-2.93	30.84	-69.08	-18.43
Debt to Total Capital	69.42%	70.65%	70.76%	68.31%	76.63%	77.33%	115.81%	124.31%	127.78%	127.24%	144.78%
Short-Term Debt to Total Capital	6.85%	6.81%	7.17%	1.54%	1.88%	1.98%	21.54%	15.85%	15.07%	34.07%	0.00%
Long-Term Debt to Total Capital	62.57%	63.83%	63.59%	66.76%	74.75%	75.34%	94.26%	108.46%	112.72%	93.17%	144.78%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	30.58%	29.35%	29.24%	31.69%	23.37%	22.67%	-15.81%	-24.31%	-27.78%	-27.24%	-44.78%
Debt to EBITDA	5.42	5.52	5.32	5.03	35.43	-31.43	-41.34	-42.38	9.65	9.20	6.32
Net Debt to EBITDA	4.79	4.89	4.70	4.90	34.48	-30.47	-40.57	-41.74	8.36	7.77	6.30
Long-Term Debt to EBITDA	4.88	4.99	4.78	4.91	34.56	-30.63	-33.65	-36.98	8.51	6.74	6.32
Debt to NOPAT	28.67	29.47	26.13	23.58	-12.74	-13.40	-10.73	-11.26	110.30	125.07	86.69
Net Debt to NOPAT	25.35	26.12	23.07	23.01	-12.41	-12.99	-10.54	-11.10	95.63	105.66	86.32
Long-Term Debt to NOPAT	25.84	26.63	23.49	23.04	-12.43	-13.06	-8.74	-9.83	97.29	91.58	86.69
Altman Z-Score	2.43	2.46	2.26	2.41	2.30	0.32	2.23	2.28	0.41	0.25	0.25
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.11	1.16	1.09	1.09	1.08	1.13	0.86	0.86	0.58	0.49	0.41
Quick Ratio	0.44	0.47	0.43	0.37	0.39	0.33	0.09	0.10	0.40	0.37	0.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	649	631	234	88	226	359	1,363	1,417	96	1,102	62
Operating Cash Flow to CapEx	291.09%	0.00%	410.25%	62.37%	134.55%	-112.25%	35.11%	-437.16%	0.00%	0.00%	-77.99%
Free Cash Flow to Firm to Interest Expense	19.47	17.71	6.53	2.41	6.14	14.81	52.40	48.80	5.30	34.07	3.57
Operating Cash Flow to Interest Expense	3.35	-1.49	3.24	0.75	1.93	-1.45	1.45	-5.94	3.75	-1.55	-1.50
Operating Cash Flow Less CapEx to Interest Expense	2.20	-1.48	2.45	-0.45	0.50	-2.74	-2.67	-7.30	4.59	0.12	-3.43
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.97	1.98	1.99	2.09	2.20	0.15	2.27	2.36	0.78	0.75	0.85
Accounts Receivable Turnover	15.18	14.60	15.78	15.86	16.61	1.19	25.02	24.88	17.58	7.94	16.73
Inventory Turnover	6.72	6.79	6.95	7.26	7.56	0.00	13.11	13.08	20.74	1.99	20.49
Fixed Asset Turnover	18.42	0.00	20.01	20.52	20.32	1.45	28.55	28.35	10.93	7.26	11.31
Accounts Payable Turnover	7.08	6.93	6.48	6.71	7.00	0.00	9.80	10.18	4.07	1.67	4.11
Days Sales Outstanding (DSO)	24.05	25.00	23.13	23.01	21.97	307.74	14.59	14.67	20.76	45.95	21.82
Days Inventory Outstanding (DIO)	54.34	53.75	52.49	50.24	48.25	0.00	27.85	27.90	17.60	183.24	17.82
Days Payable Outstanding (DPO)	51.56	52.68	56.35	54.42	52.15	0.00	37.23	35.84	89.65	218.27	88.71
Cash Conversion Cycle (CCC)	26.83	26.06	19.27	18.83	18.07	307.74	5.21	6.74	-51.30	10.93	-49.07
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,779	2,804	2,700	2,714	2,369	2,459	1,309	1,316	1,377	1,369	1,223
Invested Capital Turnover	3.36	3.35	3.75	3.88	4.16	0.28	5.36	5.34	1.95	1.42	2.09
Increase / (Decrease) in Invested Capital	-598	-625	-220	-71	-409	-345	-1,391	-1,398	-75	-1,090	-86
Enterprise Value (EV)	3,329	4,029	2,872	3,049	2,812	2,586	2,718	2,535	2,055	2,008	2,036
Market Capitalization	1,474	2,120	1,033	1,210	1,008	698	697	371	217	174	262
Book Value per Share	$12.08	$11.70	$11.25	$11.34	$7.33	$7.39	($3.67)	($5.56)	($5.96)	($6.08)	($7.19)
Tangible Book Value per Share	($14.07)	($14.16)	($14.38)	($14.02)	($13.81)	($13.54)	($22.24)	($23.60)	($23.60)	($23.55)	($24.25)
Total Capital	3,022	3,049	2,943	2,760	2,419	2,518	1,778	1,767	1,659	1,706	1,230
Total Debt	2,098	2,154	2,083	1,885	1,854	1,947	2,059	2,197	2,120	2,171	1,781
Total Long-Term Debt	1,891	1,946	1,872	1,842	1,808	1,898	1,676	1,917	1,870	1,589	1,781
Net Debt	1,854	1,909	1,839	1,840	1,804	1,888	2,020	2,164	1,838	1,834	1,774
Capital Expenditures (CapEx)	38	-0.13	28	44	53	31	107	39	-15	-54	33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	175	266	163	180	143	236	-31	-87	-431	-370	-402
Debt-free Net Working Capital (DFNWC)	418	511	407	225	193	296	6.99	-54	-149	-33	-395
Net Working Capital (NWC)	211	303	196	182	147	246	-376	-334	-399	-615	-395
Net Nonoperating Expense (NNE)	33	29	46	30	113	39	841	169	78	18	64
Net Nonoperating Obligations (NNO)	1,854	1,909	1,839	1,840	1,804	1,888	1,590	1,745	1,838	1,834	1,774
Total Depreciation and Amortization (D&A)	71	74	64	62	65	43	59	64	30	62	66
Debt-free, Cash-free Net Working Capital to Revenue	1.69%	2.55%	1.55%	1.68%	1.34%	31.90%	-0.29%	-0.81%	-15.61%	-13.63%	-15.20%
Debt-free Net Working Capital to Revenue	4.04%	4.90%	3.86%	2.11%	1.80%	39.92%	0.07%	-0.51%	-5.40%	-1.23%	-14.91%
Net Working Capital to Revenue	2.04%	2.91%	1.86%	1.71%	1.38%	33.18%	-3.50%	-3.11%	-14.45%	-22.63%	-14.91%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.23	($0.29)	($0.42)	($0.17)	($3.85)	($0.32)	($11.30)	($1.94)	($0.75)	($0.08)	($1.16)
Adjusted Weighted Average Basic Shares Outstanding	76.60M	76.50M	77.10M	77.11M	77.25M	76.61M	77.24M	77.35M	76.44M	76.58M	76.90M
Adjusted Diluted Earnings per Share	$0.23	($0.29)	($0.42)	($0.17)	($3.85)	($0.32)	($11.30)	($1.94)	($0.75)	($0.08)	($1.16)
Adjusted Weighted Average Diluted Shares Outstanding	76.60M	76.50M	77.10M	77.11M	77.25M	76.61M	77.24M	77.35M	76.44M	76.58M	76.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	76.60M	76.50M	77.10M	77.11M	77.25M	76.61M	77.24M	77.35M	76.44M	76.58M	76.90M
Normalized Net Operating Profit after Tax (NOPAT)	71	26	35	37	-166	23	-26	19	13	-4.50	-6.57
Normalized NOPAT Margin	2.69%	0.99%	1.30%	1.37%	-6.16%	3.47%	-3.82%	2.72%	0.00%	-0.72%	-1.07%
Pre Tax Income Margin	0.79%	-1.04%	-0.63%	-0.51%	-11.11%	-0.80%	-12.46%	-0.52%	0.00%	-2.59%	-14.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.63	0.24	0.53	0.62	-7.14	0.78	-2.27	0.87	2.19	0.50	-2.07
NOPAT to Interest Expense	1.52	0.19	0.40	0.46	-4.98	0.57	-1.07	0.64	1.21	0.37	-1.42
EBIT Less CapEx to Interest Expense	0.48	0.24	-0.26	-0.58	-8.58	-0.51	-6.38	-0.48	3.04	2.16	-4.00
NOPAT Less CapEx to Interest Expense	0.37	0.19	-0.39	-0.73	-6.42	-0.72	-5.19	-0.72	2.05	2.04	-3.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.41%	0.00%	0.00%	-0.92%	-0.80%	-1.17%

Financials Breakdown Chart

Key Financial Trends

Accendra Health (NYSE: ACH) has been under significant pressure over the last several years, and the latest quarter shows only a partial improvement. Revenue in Q1 2026 fell to $627.8 million from $673.9 million a year earlier, while the company reported a net loss of $6.5 million. Operating income was positive at $17.1 million, but interest expense remained heavy at $32.3 million, which pushed the company back into a pre-tax loss.

On the cash flow side, Q1 2026 looks mixed. Operating cash flow was still negative at -$50.1 million, but the company generated $53.9 million from investing activities, helped by $96.4 million in asset sales. Financing activity was also positive, with $51.1 million in net financing cash inflow, largely from new debt issuance. That pushed total cash higher by $54.9 million for the quarter.

The balance sheet remains the biggest concern. As of Q1 2026, ACH had $336.9 million in cash but also $2.1 billion in debt, including $581.3 million in short-term debt and $1.52 billion in long-term debt. Total liabilities stood at $2.88 billion, while equity was still negative at -$464.8 million. That indicates the company is still highly leveraged and remains financially stretched.

Looking back over the last four years, the company’s revenue base has been volatile but generally weaker than in 2022-2024. Quarterly revenue in 2025-2026 was far below the 2024 run-rate, and profitability has deteriorated sharply. One bright spot is that the latest quarter showed operating profit, but the business is still not generating enough earnings to cover interest costs consistently.

Q1 2026 operating income turned positive at $17.1 million, showing some improvement in core operations.
Cash and equivalents rose to $336.9 million, giving the company more near-term liquidity.
Investing activities generated cash, supported by $96.4 million in property, plant and equipment sales.
Quarterly cash balance increased by $54.9 million, helped by financing inflows.
Revenue fell modestly year over year in Q1 2026, suggesting demand was softer than in the prior-year quarter.
Gross profit remained solid at $278.0 million, but operating expenses still consumed most of it.
Depreciation and amortization remain large, which supports cash flow add-backs but also reflects a heavy asset base.
Operating cash flow was negative at $50.1 million in Q1 2026, showing the business is still consuming cash.
Interest expense remains a major burden at $32.3 million for the quarter, limiting earnings recovery.
The balance sheet remains highly leveraged with $2.1 billion in debt and negative equity.

Overall, ACH looks like a high-risk turnaround story. The latest quarter showed some operating progress and better liquidity, but the company is still dealing with weak earnings, negative operating cash flow, and a very heavy debt load. For retail investors, the key question is whether management can sustain operating improvement fast enough to reduce leverage before interest expense and balance sheet strain become a bigger problem.

08/30/26 08:05 AM ETAI Generated. May Contain Errors.

Accendra Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Accendra Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Accendra Health's net income appears to be on an upward trend, with a most recent value of -$1.10 billion in 2025, falling from $103.41 million in 2015. The previous period was -$362.69 million in 2024. Find out what analysts predict for Accendra Health in the coming months.

Accendra Health's total operating income in 2025 was $27.46 million, based on the following breakdown:

Total Gross Profit: $1.29 billion
Total Operating Expenses: $1.26 billion

Over the last 10 years, Accendra Health's total revenue changed from $9.77 billion in 2015 to $2.76 billion in 2025, a change of -71.7%.

Accendra Health's total liabilities were at $2.91 billion at the end of 2025, a 28.4% decrease from 2024, and a 63.5% increase since 2015.

In the past 10 years, Accendra Health's cash and equivalents has ranged from $27.57 million in 2024 to $281.99 million in 2025, and is currently $281.99 million as of their latest financial filing in 2025.

Over the last 10 years, Accendra Health's book value per share changed from 15.78 in 2015 to -5.96 in 2025, a change of -137.8%.

Related Companies

Financial statements for NYSE:ACH last updated on 8/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accendra Health (ACH) Financials

Financials Breakdown Chart

Key Financial Trends

Accendra Health Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accendra Health (ACH) Financials

Annual Income Statements for Accendra Health

Quarterly Income Statements for Accendra Health

Annual Cash Flow Statements for Accendra Health

Quarterly Cash Flow Statements for Accendra Health

Annual Balance Sheets for Accendra Health

Quarterly Balance Sheets for Accendra Health

Annual Metrics And Ratios for Accendra Health

Quarterly Metrics And Ratios for Accendra Health

Financials Breakdown Chart

Key Financial Trends

Accendra Health Financials - Frequently Asked Questions

When does Accendra Health's fiscal year end?

How has Accendra Health's net income changed over the last 10 years?

What is Accendra Health's operating income?

How has Accendra Health's revenue changed over the last 10 years?

How much debt does Accendra Health have?

How much cash does Accendra Health have?

How has Accendra Health's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools